After surveying with 25 glaucoma specialists who have used Rhopressa in their clinical practice, Cantor Fitzgerald analyst Elemer Piros reiterates an Overweight rating on Aerie Pharmaceuticals with an $86 price target. In the survey, 84% of physicians indicated that the safety and efficacy of Rhopressa in their practices have either met or surpassed expectations, Piros tells investors in a research note. Further, physicians provided positive feedback from their experiences with prescribing Rhopressa, says the analyst. In addition, Piros says he was unable to identify any correlation with patient compliance or physician expectations with levels of hyperemia.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.